Tandy Muse
Family Medicine · Salt Lake City, UTNPI 1841854338
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by MML US, Inc. at 24.1% of the total. Reporting peaked in 2022 at $3,828 and has fallen 98.9% since, to $42 in 2025.
Across 155 payments — averaging $39.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MML US, Inc.$1K
- Relievant Medsystems, Inc.$1K
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$939
- Boston Scientific$282
- AstraZeneca$164
- plus $1K from 27 others
What the payments were for
- Consulting fees$81713%
- Travel & lodging$2,04534%
- Food & beverage$3,20853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MML US, Inc. | 12 | $1,462 |
| Relievant Medsystems, Inc. | 13 | $1,144 |
| AbbVie | 50 | $1,057 |
| Biohaven Pharmaceuticals, Inc. | 8 | $939 |
| Boston Scientific | 10 | $282 |
| AstraZeneca | 4 | $164 |
| Amgen | 7 | $100 |
| Collegium Pharmaceutical, Inc. | 6 | $84 |
| Johnson & Johnson | 3 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Painteq LLC | 3 | $60 |
| Bayer | 3 | $59 |
| Novo Nordisk | 4 | $58 |
| SPR Therapeutics, Inc | 2 | $51 |
| Boehringer Ingelheim | 2 | $48 |
| Eisai Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Pfizer | 2 | $35 |
| Nevro Corp. | 1 | $34 |
| Impel Pharmaceuticals Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Pear Therapeutics (US), Inc. | 1 | $21 |
| Medtronic | 1 | $19 |
| Merck | 1 | $18 |
| Gilead | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Nalu Medical, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,795
- ReActiv8$1,321
- NURTEC ODT$800
- FARXIGA$125
How this compares
$6,070 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Mark CacciamaniSalt Lake City$43K
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- David LarsenSalt Lake City$8K
- Michael CobbleSandy$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.